Trial Profile
Randomized, cohort study of standardized reduction of subcutaneous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- 17 Sep 2020 Status changed from recruiting to completed.
- 05 Oct 2017 New trial record